Tag Archives: lenalidomide

Daratumumab effective in front-line multiple myeloma

Anti-CD38 monoclonal antibody daratumumab (Darzalex) is indicated for the treatment or patients with multiple myeloma that have failed prior treatment. CD38 is a Continue reading

Surprising Efficacy of Darzalex is not Solely Due to Anti-CD38 Activity on Myeloma Cells

We have previously reviewed anti-CD38 monoclonal antibody Darzalex (daratumumab) in multiple myeloma. Daratumumab targets CD38-expressing myeloma cells through a variety of immune-mediated mechanisms (complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis) and direct apoptosis with cross-linking of receptors. Continue reading

Darzalex for Refractory Multiple Myeloma

Darzalex (daratumumab), and anti-CD38 monoclonal antibody for the treatment of patients with multiple myeloma who had already undergone at least three prior standard treatments, received FDA approval. The product was developed by J&J and Genmab. Continue reading